US-based diagnostic tests provider Chembio Diagnostics has partnered with Swiss-based Foundation for Innovative New Diagnostics (FIND) to develop a point-of-care (POC) test, DPP Fever Panel Assay, to detect several acute febrile illnesses in the Asia Pacific region.

The firms will be working over the coming year to develop a simple, rapid and cost-effective test using Chembio’s Dual Path Platform (DPP) technology.

The new multiplex test will be designed to simultaneously identify multiple life-threatening acute febrile diseases, contrary to the existing POC tests.

Chembio chief executive officer John Sperzel said: "We are pleased to collaborate with FIND toward the development of an Asia Pacific fever panel, based on our patented DPP technology.

"We are pleased to collaborate with FIND toward the development of an Asia Pacific fever panel, based on our patented DPP technology."

"We believe our platform offers the ability to develop rapid diagnostic tests that are simple, cost-effective and capable of testing for multiple pathogens simultaneously.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

"Developing such a test, to address the most common causes of fever in Asia Pacific, is aligned with our growth strategy and supports our recent decision to acquire Malaysia-based RVR Diagnostics.”

The assay will include nine tests and a quality control targeting parasitic, viral and bacterial pathogens common in the Asia Pacific region.

It will focus on fever symptoms, causing pathogens such as malaria species, dengue virus, Zika virus, chikungunya virus, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei and Orientia tsutsugamushi.

Chembio and FIND have previously partnered to develop a fever panel for four diseases, including Ebola and Marburg, with outbreak potential in Africa and South America. The panel is currently undergoing field testing in these countries.